Article in press -uncorrected proof APOA5 Ala315)Val, identified in patients with severe hypertriglyceridemia, is a common mutation with no major effects on plasma lipid levels 
Introduction
The apolipoprotein A5 gene (APOA5) was identified by comparative sequencing of human and mice DNA in 2001 (1) . Generation of transgenic and knockout mice demonstrated the role of this gene in determining plasma triglyceride (TG) levels. The transgenic mice exhibited diminished, and the knockout mice elevated levels of plasma TG, while the plasma cholesterol levels were not significantly influenced.
ApoA5 is located on TG-rich (chylomicrons and very-low-density lipoprotein) and high-density lipoprotein (HDL) particles. In comparison to other apolipoproteins, plasma concentration of apoA5 in humans is low -ranging from ;25 to 400 m/L (2) .
Nevertheless, ApoA5-ApoC3 double knockout and double transgenic mice have normal TG levels (3). In the double transgenic mice, despite the fact that plasma levels of human apoA5 are approximately 500 times lower than that of apoC3, apoA5 still has a significant effect on plasma TG levels (3) .
Almost 20 APOA5 single nucleotide polymorphisms (SNPs)/mutations have been identified wmost of them reviewed in (4)x. Two TG-raising haplotypes have been identified, APOA5*2 and APOA5*3, which can be tagged by T-1131)C and the Ser19)Trp variants, respectively, and which have been studied in a wide range of human populations, although some genderspecific and ethnicity-specific differences have been described (4) (5) (6) (7) . APOA5-1131C and 19Trp alleles have also been associated with myocardial infarction risk and coronary artery disease development (8, 9) .
ApoA5 binds to, and enhances the activity of, lipoprotein lipase in mice (10, 11) . A similar function of apoA5 in humans was confirmed by Priore Oliva et al. (12) and by Marcais et al. (13) in their studies of patients with premature truncation of APOA5. Two patients with rare APOA5 mutations, resulting in premature stop codons at positions 145 wC433)T; Gln145)Stop; (12) x and 139 wC417)T; Gln139)Stop; (13)x were reported. Plasma of the patients activated lipoprotein lipase in vitro less efficiently than control plasma from healthy individuals. These results confirmed that APOA5 is an activator of lipoprotein lipase.
To explore whether rare APOA5 mutations impacted on severe hypertriglyceridemia (HTG), we screened by resequencing the APOA5 gene (coding sequence and exon/intron boundaries) in a group of 95 patients with severe HTG.
Materials and methods

Study groups
A total of 95 unrelated Czech patients (77 males and 18 females, mean age 51.6 years, TG levels )10 mmol/L) with severe HTG were selected from the database of the Lipid Clinic of the Third Department of Medicine, Charles University, Prague and were screened for the presence of rare APOA5 mutations.
As a control population we genotyped 3202 unrelated Caucasians (1490 males and 1712 females, aged 25-67 years, plasma TG levels -10 mmol/L). These individuals were selected according to the World Health Organization (WHO) protocol for the MONICA study (Manual WHO/MNC 82.2, Nov-1983) as representative of 1% of the Czech Caucasian population sample (from nine selected districts). All participants gave their informed consent prior to the start of the study. The study was approved by the local Ethics Committee.
DNA analysis
DNA was isolated from frozen EDTA blood by the standard salt-out method (14) .
Four fragments which covered the coding region of APOA5 (exons 1-3) were amplified using the following four pairs of primers: AVF5 (59-TAA CAG GAT TTC GGG CAG TT-39) and AVR5 (59-AGA GCT AGC ACC GCT CCT TT-39) for AV5 (524 bp, cover exon 1 and exon 2); AVR3 (59-CCT CGA CCC TGG GGC CAA CGC-39) and AVF3 (59-CAA GCC TCG TCC ACG CCC CC-39) for AV3 (486 bp, cover 59 half of exon 3); AVR2 (59-GCA GCA ACT GAA GCC CTA CAC GA-39) and AVF2 (59-TCA GTC TCC TGG TCG ATG GCG-39) for AV2 (546 bp, cover middle part of exon 3); AVR1 (59-AGG AGG TGC GCC AGC GAC TT-39) and AVF1 (59-TGG GAG GCT GGG TTT GCA AAG-39) for AV1 (493 bp, cover 39 half of exon 3). Overlapping fragments of AV3, AV2 and AV1 span the whole sequence of exon 3. The amplification conditions were hot start at 958C To genotype the Ala315)Val (944C)T) variant within the APOA5 gene, oppositely oriented oligonucleotides APOA5 315F 59 TTC ACT CGC GCC ATC GAC CAG GAG ACT GAG G and APOA5 315R 59 ATC CAG ACG GGC CTG CAG CTT GCT CAG were used. PCR product (141 bp) was cleaved by restriction enzyme Hin6I (Fermentas, Burlington, Canada) and separated on 10% MADGE gel (15) in 0.5= Tris/borate/EDTA (TBE) buffer. The rare allele Val315 is characterized by an uncut fragment of 141 bp, the common allele Ala315 by fragments 91 bp and 50 bp.
Biochemical analysis
The lipoprotein parameters were measured enzymatically by the WHO Regional Lipid Reference Center, IKEM, Prague on a Roche COBAS MIRA autoanalyzer (Haffmann-La Roche, Basel, Switzerland), using conventional enzymatic methods with reagents from Hoffmann-La Roche.
Statistical analysis
Statistical analysis was performed using the x 2 -test and analysis of variance. TGs were logarithmically transformed before analysis to obtain the normal distribution of data.
Results
A C to T change was detected in the heterozygous state in APOA5 cDNA position 944 in three out of 95 HTG patients, representing a carrier frequency of 0.03 (allele frequency of 0.016). This mutation resulted in the substitution of alanine at position 315 for valine. All three carriers were middle-aged men; two of them were current smokers and had treated hypertension. One of them was obese, while the other two were overweight. None of them had diabetes or cardiovascular disease. Two of them had APO´3´3 and one APO´2´3 genotypes.
To clarify whether this variant was associated with plasma TG level, a large population sample was screened for the presence of this mutation. In 3202 individuals, we detected 22 Ala315/Val315 heterozygotes. The carrier frequency in this sample population was 0.007 (rare allele frequency of 0.003) and this frequency was lower than in the HTG group (p-0.01).
The carriers of Ala315)Val from the patient and control groups were comparable for age, body mass index, smoking and diet. Therefore, it is unlikely that these conditions could have been significant environmental and non-genetic factors in the development of HTG.
The Ala315)Val variant showed no significant linkage disequilibrium with other APOA5 variants previously genotyped in the same population group wD9s0.752 and LOD score 0.1 for T-1131)C variant; D9s1.0 and LOD score 0.26 for Ser19)Trp; and D9s1.0 and LOD score 0.28 for Val153)Met).
In this sample population, Ala315Val was not associated with significant TG raising effects, if anything, Ala315Val carriers tended to have slightly elevated plasma TG levels than Ala315 homozygotes, although these differences did not reach significance (ps0.3). There were no effects on any other lipid parameters. Table 1 shows the basic characteristics and lipid levels of all Val315 allele carriers.
Discussion
APOA5 variants are amongst the strongest genetic determinants of plasma TGs identified so far, although some ethnic and sex differences have been described. It is also not completely clear if their effect is mediated through the linkage disequilibrium with neighboring APOC3 variants. Interestingly, only three functional mutations in the APOA5 gene (Gln139) Stop and Gln145)Stop; c.161q3g)c variant completely abolished the function of the donor splice site in intron 3, suggesting a splicing defect) associated with extreme TG levels have been described so far (12, 13, 16) . The existence of the Ala315)Val variant was first mentioned by Pennacchio et al. (5) but was not analyzed further in detail. We identified a non-synonymous Ala315)Val change in the APOA5 gene in three individuals with TG levels )10 mmol/L. The Val315 allele was also detected in 22 individuals out of the total 3202 screened from a general population study, the majority of whom had lipid levels within the normal range.
We were unable to analyze the lipid profile of carriers of this mutation in detail. All patients with HTG were under treatment according to the guidelines and their current lipid and lipoprotein levels were significantly lower than the pretreatment levels, which were used for inclusion into the study. The controls from the general population sample were screened only for levels of total, HDL and low-density lipoprotein cholesterol (calculated) and TGs. Interestingly, most of the carriers of the Ala315Val from the control group had, if anything, lower TG levels than the non-carriers. We also considered whether carriage of a rare allele of either -1131T)C or Ser19Trp SNPs could account for this difference. However, none of the HTG Ala315Val carriers were heterozygous for either of these SNPs. In the population sample, five out of 22 Ala315Val carriers carried a rare allele of either T-1131)C or Ser19)Trp; however, while some of these individuals had amongst the highest TG levels for the group, several had very low TG levels, thus eliminating this as an explanation.
Despite this lack of association with plasma TG levels, the frequency of the mutation was significantly higher in the patients with HTG than in controls (p-0.01). It is possible that in order to have effects of plasma TG levels, Ala315)Val needs to be associated with some other, as yet unidentified mutation, either situated in the APOA5 gene cluster or in another gene region resulting in an interaction which leads to HTG.
We examined whether the apolipoprotein E (APOE) gene would influence this, as an association between the APOA5 and APOE variants has been reported in patients with different forms of dyslipidemias (17) (18) (19) .
We determined APOE genotypes in all individuals. In the HTG group, two Val315 carriers had APOE´3´3 genotypes and one was APOE´3´2 heterozygote. In the control group, there were 14´3´3 homozygotes, three´4´3 heterozygotes, four´3´2 heterozygotes and one´2´2 homozygote who were Val315 carriers. Thus, it is unlikely that the APOE gene acts synergistically with this APOA5 mutation in the development of HTG and this suggests that some other genes are implicated.
In our Caucasian control sample population, this mutation did not influence plasma TG levels significantly. Molecular modeling of apoA5 suggests that the residues around amino acid 315 do not play a part in either lipid binding or lipoprotein lipase activation, and the Ala)Val change is rather conservative (20) . Out of 25 carriers of this mutation, three were from the sample of HTG patients and consequently had very high TG levels, while the other carriers had levels of TG that did not correspond to this being a variant, which had generally strong effect on plasma TG levels. The higher frequency of the Ala315)Val in the HTG patients could be a chance event as the number of tested individuals was small, but further research is needed to elucidate if the presence of another genetic variant(s) or environmental factors are necessary to cause manifest HTG in APOA5 Ala315)Val carriers.
